Fig. 1 · Structure

Documents & Downloads

SNS-032 (BMS-387032)

Cat. No. A10850 CAS 345627-80-7

CDK inhibitor

SNS-032 (BMS-387032) is a highly selective and potent inhibitor of cyclin-dependent kinases (Cdks) 2, 7, and 9, with in vitro growth inhibitory effects and ability to induce apoptosis in malignant B cells.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
CDK9/CyclinT IC50 4nM
CDK2/CyclinA IC50 38nM
CDK2/CyclinE IC50 48nM
CDK7/CyclinH IC50 62nM
GSK-3α IC50 230nM
CDK5/p35 IC50 340nM
CDK1/CyclinB IC50 480nM
GSK-3β IC50 660nM
CDK4/CyclinD IC50 925nM
CDK6/CyclinD IC50 >1μM

10 targets · Scroll to view more

Cellular Effect

Cell Line Activity Value Description Reference
CWR22R IC50 0.384 μM Antiproliferative activity against human 22Rv1 cells assessed as reduction in cell viability measured after 5 days by CellTiter-Glo assay [PMID: 35925880]
HCT-116 IC50 0.458 μM Inhibition of CDK9 in human HCT116 cells assessed as phosphor-ser2 level of RNA polymerase 2 after 16 hrs by high content cellular assay [PMID: 18842409]
HCT-116 IC50 0.55 μM Inhibition of CDK9-mediated RNA pol 2 phosphorylation at ser2 in human HCT116 cells after 16 hrs by HCS assay [PMID: 18926699]
HCT-116 IC50 0.7 μM Antiproliferative activity against human HCT116 cells after 24 hrs by MTT assay [PMID: 30197029]
MCF7 IC50 1 μM Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay [PMID: 30197029]
MOLT-4 IC50 173 nM Antiproliferative activity against human MOLT4 cells incubated for 72 hrs by cell titer glo assay [PMID: 32866383]
Sf9 IC50 21 nM Inhibition of recombinant human full-length N-terminal GST-tagged CDK2/cyclinA1 expressed in baculovirus infected Sf9 insect cells using FRET-labeled Ser/Thr 12 as substrate measured after 1 hr by Z'-lyte assay [PMID: 32502343]

SNS-032 (BMS-387032) Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of SNS-032 (BMS-387032) from 3 published references. In vitro models include primary cells derived from late-stage HGSC clinical samples; KYSE30. In vivo models include nude mice bearing KYSE30 xenografts.

SNS-032 (BMS-387032) In Vitro Studies

SNS-032 treatment of primary cells derived from late-stage HGSC clinical samples showed antitumor activity in live cell viability assessments. In KYSE30 cells incubated with escalating concentrations for 72 h, MTT assessment of cell viability yielded a reported result of 0.27 μM. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Antitumor activity in primary HGSC cells

Cell-based study · primary cells derived from late-stage HGSC clinical samples [1]

Primary cells derived from late-stage HGSC clinical samples were treated with SNS-032 at 10 pM-10 μM for 72 h, with live cell viability assessed. Antitumor activity was reported across the panel of patient samples and cell lines.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
live cell viabilityReported result SNS-032 exhibited potent and clinically achievable anti-tumour activity across the panel of patient samples and cell lines[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 pM-10 μM
Exposure duration
72 h
Vehicle
DMSO
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: SNS-032

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Compounds, cell culture and cell viability assays (S44); Results > Validation of predicted HGSC-specific therapeutics (S113, S115); Fig. 5 legend (S143, S145, S146, S147)

live cell viability: live cell viability; comparator: vehicle control (DMSO) — Methods > Compounds, cell culture and cell viability assays (S44); Results > Validation of predicted HGSC-specific therapeutics (S115)

Cell viability assessment in esophageal cells

Cell-based study · KYSE30 [2]

KYSE30 cells were incubated with escalating concentrations for 72 h. Cell viability was assessed by MTT assay, with a reported result of 0.27 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell viability was examined by MTT assayIC50 0.27 μM[2]

Literature-Reported Treatment Conditions

Treatment concentration
escalating concentrations
Exposure duration
72 h
Method
incubated with
Reported limits
Not stated in the sentences used: vehicle, control.
Methods and source locations

Compound reported in the paper: SNS-032

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > SNS-032 inhibits the growth of ESCC cells (S8, S18); Materials and methods > Cell viability assay (S143)

cell viability was examined by MTT assay: cell viability was examined by MTT assay — Results > SNS-032 inhibits the growth of ESCC cells (S8, S18)

SNS-032 (BMS-387032) In Vivo Studies

SNS-032 administered intraperitoneally at 15 mg/kg/day produced a lower tumor growth curve than vehicle in nude mice bearing KYSE30 xenografts. In female NSG mice bearing MDA-MB-468 xenografts, weekly intravenous SNS-032 at 5 mg/kg for 4 weeks yielded tumor volumes of 187.9 ± 34.7 mm3, compared with 308.1 ± 34.12 mm3 with vehicle. [2,3]

Tumor growth in esophageal xenografts

Animal study · nude mice bearing KYSE30 xenografts [2]

Nude mice bearing KYSE30 xenografts received SNS-032 intraperitoneally at 15 mg/kg/day. The tumor growth curve was lower in the SNS-032-treated group than in vehicle-treated controls.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
tumor growth curve (tumor volume versus time)Reported result the tumor growth curve (tumor volume versus time) was much lower in the SNS-032-treated group, compared with than the vehicle-treated control ones[2]

Conditions shared by the study groups

Route
intraperitoneally (i.p.) injected
Treatment course
on a 3-day-on/2-day-off schedule
Vehicle
PBS with DMSO <0.1%
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
SNS-032 15 mg/kg/dayvehicle-treated control onesthe tumor growth curve (tumor volume versus time) was much lower in the SNS-032-treated group, compared with than the vehicle-treated control ones[2]
SNS-032 15 mg/kg/day
Model: nude mice bearing KYSE30 xenografts
Methods and source locations

Compound reported in the paper: SNS-032

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > SNS-032 inhibits ESCC cell growth in nude mice (S89, S91); Materials and methods > Animal experiments (S186, S188)

tumor growth curve (tumor volume versus time): tumor growth curve (tumor volume versus time); comparator: vehicle-treated control ones — Results > SNS-032 inhibits ESCC cell growth in nude mice (S91)

SNS-032 15 mg/kg/day · Results > SNS-032 inhibits ESCC cell growth in nude mice (S91); Materials and methods > Animal experiments (S188)

Tumor volumes in breast cancer xenografts

Animal study · Female NSG mice; MDA-MB-468 xenografts (n = 4) [3]

Female NSG mice bearing MDA-MB-468 xenografts received SNS-032 at 5 mg/kg by weekly intravenous injections for 4 weeks. Tumor volumes were 187.9 ± 34.7 mm3 with SNS-032 and 308.1 ± 34.12 mm3 with vehicle.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumors were measured with calipers and volumes were calculatedtumor volume 187.9 ± 34.7 mm3[3]

Conditions shared by the study groups

Route
intravenous injections
Treatment course
weekly injections for 4 weeks
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
SNS-032 5 mg/kgvehicleday 46: vehicle (308.1 ± 34.12 mm3), SNS-032 (187.9 ± 34.7 mm3)[3]
SNS-032 5 mg/kg
Model: Female NSG mice; MDA-MB-468 xenografts (n = 4)
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: SNS-032

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > In vivo xenograft treatment studies (S128, S131, S132, S135); Results > ADC restricts orthotopic xenograft growth (S243); Figure 6. legend (S342)

Tumors were measured with calipers and volumes were calculated: Tumors were measured with calipers and volumes were calculated; comparator: vehicle — Materials and Methods > In vivo xenograft treatment studies (S135); Results > ADC restricts orthotopic xenograft growth (S243)

SNS-032 5 mg/kg · Materials and Methods > In vivo xenograft treatment studies (S132); Results > ADC restricts orthotopic xenograft growth (S243)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 345627-80-7
Applications CDK inhibitor
Formula C17H24N4O2S2
Molecular Weight 380.5
Synonyms BMS-387032
SMILES
CC(C)(C)C1=CN=C(O1)CSC2=CN=C(S2)NC(=O)C3CCNCC3

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 74 mg/mL (194.46 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
30% PEG400+0.5% Tween80+5% propylene glycol

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

SNS-032 (BMS-387032) Research References

  1. [1] Quintela M, James DW, Garcia J, et al. In silico enhancer mining reveals SNS-032 and EHMT2 inhibitors as therapeutic candidates in high-grade serous ovarian cancer. Br J Cancer (2023). PMID: 37120667 DOI: 10.1038/s41416-023-02274-2 Source material
  2. [2] Zeng H, Yang H, Song Y, et al. Transcriptional inhibition by CDK7/9 inhibitor SNS-032 suppresses tumor growth and metastasis in esophageal squamous cell carcinoma. Cell Death Dis (2021). PMID: 34741018 DOI: 10.1038/s41419-021-04344-w Source material
  3. [3] Cheung A, Chenoweth AM, Johansson A, et al. Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth. Clin Cancer Res (2024). PMID: 38772416 DOI: 10.1158/1078-0432.CCR-23-3110 Source material

Added to your cart

View Cart Checkout
Loading...